Cohort of HIV-infected Children

ANRS CO10 EPF - Cohort of HIV-infected Children

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03235258

Acronym

EPF

Enrollment

812

Registered

2017-08-01

Start date

2004-07-31

Completion date

2020-06-30

Last updated

2021-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children Infected by HIV

Keywords

HIV Infection, Adolescent

Brief summary

The purpose of this study is to describe the conditions of access to early treatment of children infected with HIV, their management on the long-term, and impact on growth, clinical and immunovirological prognosis, adherence to treatment, living conditions

Detailed description

The CO10 EPF paediatric cohort includes therapeutic, clinical and biological detailed questionnaires. The data are collected by the doctors every three months to 2 years and then every 6 months until to 18 years or every year by a simplified questionnaire if medical follow up continues outside of a participating site. After 18 years of age, the patients are eligibile for the ANRS CO19-Coverte cohort.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 13 Years

Healthy volunteers

Inclusion criteria

* HIV-infected children born to mothers included in ANRS-CO1 EPF or children under the age of 13 newly entered in care management with no prior antiretroviral therapy, whose mother was or not included in ANRS-CO1 EPF

Exclusion criteria

* \>= 13 years * refusal of legal representative of the child * antiretroviral therapy started before the entry in care management * care management for over 6 months before inclusion

Design outcomes

Primary

Measure	Time frame	Description
Conditions of access to early treatment	At inclusion and every six months up to 18 years	social factors (Geographical origin, living conditions, school level, age) and infection stage

Secondary

Measure	Time frame	Description
Puberty stage	At 8 years and every six months up to 18 years	Tanner classification
Clinical prognosis	At inclusion and every six months up to 18 years	Health status (lipodystrophy, metabolic abnormalities, cardiovascular diseases, encephalopathy, Developmental delay, CDC stage)
Immuno virological prognosis	At inclusion and every six months up to 18 years	HIV RNA\<50c/mL, CD4 cells count \> 500 cells/mL, Genotypic resistance
Prognosis of patient coinfected by CMV or VHC	At inclusion and every six months up to 18 years	Adverse events of treatments (complications)
Sexuality	At 15 years and every six months up to 18 years	sexual risk behaviour (age at first intercourse, condom use at first, contraception, pregnancy, interruption of pregnancy)

Countries

France

Outcome results